Gapping down
In reaction to earnings/guidance:
- NCR -18.3%, FFIV -8.7%, CHKP -7%, JNPR -6.4%, DB -6.3%, COF -5.5%, ETR -5%, GOOG -4.4%, GRMN -4.3%, EW -3.7%, PRG -3.7%, TXN -3.4%, HIW -3.4%, TPB -3.2%, BA -3.1%, DAN -2.4%, ACMR -2.1%, APAM -1.5%, BHE -1.4%, HOG -1.4%, MKSI -1.2%, TENB -0.9%, ROL -0.9%, OSK -0.7%
Other news:
- MOLN -36.8% (MOLN to regain global rights for MP0310 from AMGN)
- SEV -10.3% (launches proposed follow-on offering of 10 mln shares)
- GMDA -5.9% (updated one-year post-transplant data presented on omidubicel at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings)
- MNKD -4.8% (presented a poster at the 15th International Conference on Advanced Technologies & Treatments for Diabetes)
- DCPH -4.1% (prices offering of common stock and pre-funded warrants)
- HOOD -3.7% (eliminates 9% of its full-time employees)
- ETD -1.4% (increases dividend)
- TWTR -1% (discloses $1 bln parent termination fee in merger agreement with Elon Musk)
Analyst comments:
- COF -5.5% (downgraded to Neutral from Overweight at Piper Sandler)
- JBLU -2.2% (downgraded to Underweight from Overweight at JP Morgan)
- SKYW -1.6% (downgraded to Mkt Perform from Outperform at Raymond James)